Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient.
Ferdinand BigirimanaSigi Van den WijngaertChristelle FossoKarolien StoffelsCharlotte MartinEvelyne MaillartPhilippe ClevenberghPublished in: Case reports in infectious diseases (2023)
We report a hemodialysis MDR HIV-infected patient switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and did not present any clinical or biological drug-related side effects. The combination of lenacapavir plus fostemsavir looks promising in terms of safety and efficacy even in patients with end-stage renal disease awaiting renal transplant. Both drugs are first in class ARVs so that there is no cross resistance with previous drugs, maintaining their efficacy against MDR HIV.
Keyphrases
- hiv infected
- end stage renal disease
- multidrug resistant
- peritoneal dialysis
- chronic kidney disease
- antiretroviral therapy
- hiv infected patients
- human immunodeficiency virus
- drug resistant
- gram negative
- hiv positive
- case report
- acinetobacter baumannii
- hiv aids
- klebsiella pneumoniae
- drug induced
- sars cov
- cystic fibrosis
- hepatitis c virus
- hiv testing
- men who have sex with men
- adverse drug